Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis

Key Points

• This research aims to evaluate the efficacy and safety of nemolizumab compared to other anti-interleukin monoclonal antibodies in treating moderate-to-severe atopic dermatitis.
• Conducted a network meta-analysis of existing studies
• Compared efficacy outcomes such as EASI-75 and IGA success
• Evaluated safety profile of nemolizumab versus anti-IL monoclonal antibodies
• Focused on combination treatment with topical therapies
• Nemolizumab showed similar efficacy in achieving EASI-75 and IGA success compared to anti-IL mAbs
• The safety profile of nemolizumab was comparable to that of the anti-interleukin therapies
• Nemolizumab effectively improved itch associated with atopic dermatitis
• The findings suggest that nemolizumab is a well-tolerated option for management of atopic dermatitis.